

VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Madrid, Spain
20–22 June 2007

Abstracts

President

G Bonadonna (Milan, Italy)

Chairmen

H Cortés-Funes (Madrid, Spain)

L Gianni (Milan, Italy)

Scientific Committee

C Arteaga (Nashville, USA)

J Baselga (Barcelona, Spain)

P Conte (Modena, Italy)

H Cortés-Funes (Madrid, Spain)

L Gianni (Milan, Italy)

G Hortobagyi (Houston, USA)

C Hudis (New York, USA)

L Norton (New York, USA)

Faculty

A Antón (Zaragoza, Spain)

E Alba (Málaga, Spain)

C Arteaga (Nashville, USA)

J Baselga (Barcelona, Spain)

FA Calvo (Madrid, Spain)

LA Carey (Chapel Hill, USA)

E Ciruelos (Madrid, Spain)

R Colomer (Madrid, Spain)

P Conte (Modena, Italy)

H Cortés-Funes (Madrid, Spain)

M Cristofanilli (Houston, USA)

D Dershaw (New York, USA)

M Esteller (Madrid, Spain)

F Esteva (Houston, USA)

J Garber (Boston, USA)

L Gianni (Milan, Italy)

J Giralt (Barcelona, Spain)

A González (Madrid, Spain)

V Guillem (Valencia, Spain)

A Howell (Manchester, UK)

G Hortobagyi (Houston, USA)

C Hudis (New York, USA)

W Janni (Munich, Germany)

S Khan (Chicago, USA)

R Kramer (Houston, USA)

A Lluch-Hernández (Valencia, Spain)

F López-Ríos (Madrid, Spain)

EP Mamounas (Canton, USA)

M Martín (Madrid, Spain)

C Mendiola (Madrid, Spain)

R Noguero (Madrid, Spain)

L Norton (New York, USA)

R Orecchia (Milan, Italy)

EA Perez (Florida, USA)

J María Pérez Aznar (Madrid, Spain)

J-Y Petit (Milan, Italy)

L Pusztai (Houston, USA)

G Robb (Houston, USA)

JM San Román (Madrid, Spain)

I Smith (London, UK)

MJ Van de Vijver (Amsterdam, The Netherlands)

C Vázquez (Valencia, Spain)

J Antonio Virizuela (Sevilla, Spain)

E Winer (Boston, USA)

Contents

Speaker Abstracts

Introduction

- S1 **Assessing prognosis for early breast cancer: clinical versus genetic profiles**
GN Hortobagyi

SYMPOSIUM I

Prognostic and Risk Factors (Part I)

- S2 **Circulating tumor cells as predictors of recurrence in primary breast cancer**
W Janni
- S3 **Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer**
M Cristofanilli

Prognostic and Risk Factors (Part II)

- S4 **Gene expression profiling for prognosis of breast cancer**
M van de Vijver
- S5 **Molecular and gene expression-based predictors of response to preoperative chemotherapy**
L Pusztai
- S6 **Role of MR and digital mammography for screening**
DD Dershaw

SYMPOSIUM II

New Strategies for Primary Treatment (Part I)

- S7 **Surgical issues in the breast and axillary nodes in patients treated with neoadjuvant systemic therapy**
EP Mamounas
- S8 **Treatment of the intact primary in women with metastatic breast cancer**
SA Khan, H Hazard, D Scholtens
- S9 **Immediate versus delayed breast reconstruction**
GL Robb

New Strategies for Primary Treatment (Part II)

- S10 **The nipple sparing mastectomy: a 5-year experience at the European Institute of Oncology of Milan**
JY Petit, U Veronesi, R Orecchia, A Luini
- S11 **Partial breast irradiation and intraoperative radiotherapy**
R Orecchia

SYMPOSIUM III

Controversies in Clinical Practice (Part I)

- S12 **Current status of adjuvant endocrine therapy for premenopausal patients with primary breast cancer**
A Howell
- S13 **Triple-negative (basal-like) breast cancer: a new entity**
LA Carey

- S14 **Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)**
PF Conte, V Guarneri, C Bengala

- S15 **Present and future role of bisphosphonates in treatment**
GN Hortobagyi

SYMPOSIUM IV

Primary Systemic Therapy and Adjuvant Treatment

- S16 **Standards and future strategies in adjuvant chemotherapy treatments**
C Hudis, H McArthur
- S17 **Adjuvant hormonal therapy for postmenopausal women**
EP Winer
- S18 **Preoperative systemic treatment for operable disease: biological correlates of response to neoadjuvant treatment**
GN Hortobagyi
- S19 **Neoadjuvant endocrine therapy: clinical and biological issues**
IE Smith

SYMPOSIUM V

Advances in Metastatic Disease

- S20 **Chemotherapy in metastatic disease: an overview**
IE Smith

SYMPOSIUM VI

Targeted Therapy: Present and Future

- S21 **Epigenetics of breast cancer**
M Esteller
- S22 **Present and future roles of bevacizumab in breast cancer**
H Cortés-Funes
- S23 **Novel strategies for HER-2-positive metastatic disease: mechanisms and therapeutic options to overcome trastuzumab resistance**
FJ Esteva

Posters

- P1 **Prognostic factors for the node-negative breast cancers**
B-W Park, J-H Kim, K-S Kim, KS Lee
- P2 **Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study**
F Carabantes-Ocón, E Saez-Lara, L Burgos-Garcia, E Villar-Chamorro, A Casaus-Hazañas, S Luna, C Martínez
- P3 **Do breast cancer tumours downsize as well as downgrade with neoadjuvant chemotherapy?**
M Dani, J McDonnell, S Karp, V Jaffe
- P4 **Saline instillation into the cavity after conservation surgery for breast cancer is a safe way of improving cosmesis**
M Dani, T Tahmid, J McDonnell, V Jaffe

- P5 A safety and efficacy study of bleomycin sulfate and electroporation in patients with metastatic or locally recurrent breast cancer**
V Paramanov, O Tyurin, S Polenkov, PM Goldfarb
- P6 Predictive value of HER2 expression for the selection of adjuvant chemotherapy in breast cancer patients**
A Hegmane, U Vikmanis
- P7 Axillary study before surgery in patients with breast cancer**
M Izquierdo, R Fabregas, J Feu, L Lopez Marin, B Navarro, C Ara, M Cusido, F Tresserra
- P8 Resveratrol downregulates acetyl-CoA carboxylase alpha and fatty acid synthase by activating AMP-activated protein kinase and suppressing the mammalian target of rapamycin signal pathway**
S Yoon, B-W Park, K-S Kim
- P9 Partial breast irradiation with an electron beam for patients submitted to conservative surgery**
MAC Maia, MM Netto, MS Maciel, JC Donoso, JV Salvajoli, ACA Pellizzon, RC Fogaroli, KW Bocalletti, C Tanous
- P10 Positive axillary lymph node metastases in T1-T3 breast cancer: prognostic value of extracapsular extension**
S Maksimovic, Z Gojkovic, M Opric
- P11 Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer**
S Menjón-Beltrán, R Olivencia-Dueso, E González-Jiménez, MJ Titos
- P12 Clinical role of trastuzumab in metastatic breast cancer: experience of a center**
S Menjón-Beltrán, R Olivencia, E Gonzalez
- P13 BRCA1a has antitumor activity in triple-negative breast cancers**
C Yuli, N Shao, G Oprea-Ilies, J Okoli, ESP Reddy, VN Rao
- P14 Diagnosis of familial breast cancer by multiplex PCR and clinical parameters**
H Rassi
- P15 Novel method of sentinel lymph node detection in malignant tumors using preparation 'UNIMAG'**
B Surguladze, Z Rati, T Tskitishvili
- P16 Frequency of febrile neutropenia in patients treated with taxane/epirubicine and colony-stimulating growth factors for breast cancer: comparison of filgrastim/lenograstim with pegfilgrastim**
W Schipping, R Holub, N Dandachi, T Bauernhofer
- P17 Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial**
I Sestak, R Edwards, A Howell, J Cuzick
- P18 Minimal residue disease (MRD)**
A Zaidi, G Tripuraneni, S Weller, B Ward, HD Sinnett, RC Coombes, MJ Slade

Proffered Papers

- P19 Algorithm for identification of individuals with hereditary predisposition to breast cancer and other breast cancer-associated forms of malignant neoplasms**
IV Zalutsky, NN Antonenkova, GM Porubova
- P20 Identification of individuals with hereditary predisposition to breast cancer and other breast cancer-associated forms of malignant neoplasms: data of the Belarusian Cancer Registry**
IV Zalutsky, NN Antonenkova
- P21 Tachosil® to reduce the morbidity of axillary lymph node dissection in breast cancer**
E Barranger, O Morel, G Akerman, C Malartic, D Clement
- P22 First clinical results on the potential of intraoperative imaging for sentinel lymph node biopsy in breast cancer**
E Barranger, K Kerrou, S Pitre, MA Duval, C Coutant, R Siebert, J Talbot, Y Charon, S Uzan
- P23 Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer**
V Guarneri, A Frassoldati, F Piacentini, K Cagossi, L Cavanna, A Michelotti, G Jovic, S Giovannelli, G Ficarra, C Oliva, P Conte
- P24 Significance of nuclear medicine: ^{99m}Tc-MDP in the detection of breast cancer bone metastasis**
P Karan, AN Tiwari, R Pisal

Index to authors

Index to authors

Akerman, G, P21
 Antonenkova, NN, P19, P20
 Ara, C, P7

Barranger, E, P21, P22
 Bauernhofer, T, P16
 Bengala, C, S14
 Bocalletti, KW, P9
 Burgos-Garcia, L, P2

Cagossi, K, P23
 Carabantes-Ocón, F, P2
 Carey, LA, S13
 Casaus-Hazañas, A, P2
 Cavanna, L, P23
 Charon, Y, P22
 Clement, D, P21
 Conte, P, P23
 Conte, PF, S14
 Coombes, RC, P18
 Cortés-Funes, H, S22
 Coutant, C, P22
 Cristofanilli, M, S3
 Cusido, M, P7
 Cuzick, J, P17

Dandachi, N, P16
 Dani, M, P3, P4
 Dershaw, DD, S6
 Donoso, JC, P9
 Duval, MA, P22

Edwards, R, P17
 Esteller, M, S21
 Esteva, FJ, S23

Fabregas, R, P7
 Feu, J, P7
 Ficarra, G, P23
 Fogaroli, RC, P9
 Frassoldati, A, P23

Giovannelli, S, P23
 Gojkovic, Z, P10
 Goldfarb, PM, P5
 Gonzalez, E, P12
 González-Jiménez, E, P11
 Guarneri, V, S14, P23

Hazard, H, S8
 Hegmane, A, P6
 Holub, R, P16
 Hortobagyi, GN, S1, S15, S18
 Howell, A, S12, P17
 Hudis, C, S16

Izquierdo, M, P7

Jaffe, V, P3, P4
 Janni, W, S2
 Jovic, G, P23

Karan, P, P24
 Karp, S, P3
 Kerrou, K, P22

Khan, SA, S8
 Kim, J-H, P1
 Kim, K-S, P1, P8

Lee, KS, P1
 Lopez Marin, L, P7
 Luini, A, S10
 Luna, S, P2

Maciel, MS, P9
 Maia, MAC, P9
 Maksimovic, S, P10
 Malartic, C, P21
 Mamounas, EP, S7
 Martínez, C, P2
 McArthur, H, S16
 McDonnell, J, P3, P4
 Menjón-Beltrán, S, P11, P12
 Michelotti, A, P23
 Morel, O, P21

Navarro, B, P7
 Netto, MM, P9

Okoli, J, P13
 Oliva, C, P23
 Olivencia, R, P12
 Olivencia-Dueso, R, P11
 Oprea-Ilieș, G, P13
 Opric, M, P10
 Orecchia, R, S10, S11

Paramanov, V, P5
 Park, B-W, P1, P8
 Pellizzon, ACA, P9
 Petit, JY, S10
 Piacentini, F, P23
 Pisal, R, P24
 Pitre, S, P22
 Polenkov, S, P5
 Porubova, GM, P19
 Pusztai, L, S5

Rao, VN, P13
 Rassi, H, P14
 Rati, Z, P15
 Reddy, ESP, P13
 Robb, GL, S9

Saez-Lara, E, P2
 Salvajoli, JV, P9
 Schippinger, W, P16
 Scholtens, D, S8
 Sestak, I, P17
 Shao, N, P13
 Siebert, R, P22
 Sinnett, HD, P18
 Slade, MJ, P18
 Smith, IE, S19, S20
 Surguladze, B, P15

Tahmid, T, P4
 Talbot, J, P22
 Tanous, C, P9
 Titos, MJ, P11

Tiwari, AN, P24
 Tresserra, F, P7
 Tripuraneni, G, P18
 Tskitishvili, T, P15
 Tyurin, O, P5

Uzan, S, P22

van de Vijver, M, S4
 Veronesi, U, S10
 Vikmanis, U, P6
 Villar-Chamorro, E, P2

Ward, B, P18
 Weller, S, P18
 Winer, EP, S17

Yoon, S, P8
 Yuli, C, P13

Zaidi, A, P18
 Zalutsky, IV, P19, P20